Peluntamig (PT217): clinical trials recruiting now

Fewer than 3 recruiting trials found.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase breakdown

Phase 1 1 Phase 2 1

Condition	Trials
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	1
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)	1
Large Cell Neuroendocrine Cancer (LCNEC)	1
Lung cancer	1
Neuroendocrine Carcinomas (NEC)	1
Neuroendocrine Prostate Cancer (NEPC)	1
Prostate cancer	1
Small Cell Lung Cancer (SCLC)	1

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations

1 recruiting trial across 8 conditions.

No. For the full record, search ClinicalTrials.gov.